Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent

This article originally appeared here.
Share this content:
Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent
Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent

WEDNESDAY, July 5, 2017 (HealthDay News) -- Therapeutic inertia occurs in 19.1 percent of patients with type 2 diabetes with hemoglobin A1c (HbA1c) ≥8 percent on two or more non-insulin antidiabetic drugs (NIADs), according to a study published online June 28 in Diabetes, Obesity and Metabolism.

Manel Mata-Cases, M.D., Ph.D., from the Institut Universitari d'Investigació en Atenció Primària Jordi Gol in Barcelona, Spain, and colleagues examined the patterns and predictors of treatment intensification in patients with type 2 diabetes.

The researchers found that 26.2 percent of the 23,678 patients with HbA1c ≥7 percent were censored without treatment intensification after a median follow-up of 4.2 years. Therapeutic inertia, defined as no intensification if Hba1c was ≥8 percent at baseline or during follow-up, was seen in 18.1 percent of the 12,730 patients with HbA1c of ≥8 percent at baseline or during follow-up. The mean HbA1c values at initiation of insulin and NIAD were 9.4 ± 1.5 and 8.7 ± 1.3 percent, respectively, in the overall cohort. The median time to first intensification was 17.1 and 10.1 months in patients with HbA1c 8.0 to 9.9 percent and >10 percent, respectively. HbA1c values 8.0 to 9.9 percent and >10 percent and diabetes duration ≥20 years were variables strongly associated with intensification (subhazard ratios, 1.7, 2.5, and 1.25, respectively).

"Both the HbA1c thresholds and the time until therapy intensification exceeded current recommendations," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments

Online Nursing Education Can Up Patient Use of VTE Prophylaxis

Online Nursing Education Can Up Patient Use of ...

Online training aims to make sure those hospitalized get treatment to prevent venous thromboembolism

On-Pump CABG Leads to Higher Rates of Five-Year Survival

On-Pump CABG Leads to Higher Rates of Five-Year ...

Study compared coronary-artery bypass grafting surgery, with/without cardiopulmonary bypass

is free, fast, and customized just for you!

Already a member?

Sign In Now »